| Identification | Back Directory | [Name]
TOPOTECAN-D6 | [CAS]
1044904-10-0 | [Synonyms]
Hycamtin-d6
TOPOTECAN-D6
NSC-609669-d6
SKF-104864A-d6
(4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[346-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(4S)-10-[(Dimethylamino-d6)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3’,4’,6-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione | [Molecular Formula]
C23H23N3O5 | [MOL File]
1044904-10-0.mol | [Molecular Weight]
421.446 |
| Chemical Properties | Back Directory | [Appearance]
Light Yellow to Greenish Powder | [Melting point ]
213-218°C (dec) | [storage temp. ]
-20°C Freezer | [solubility ]
aqueous acid: soluble; DMSO: slightly; Methanol: soluble | [form ]
A solid | [color ]
Light yellow to yellow | [Stability:]
Hygroscopic | [CAS DataBase Reference]
1044904-10-0 |
| Hazard Information | Back Directory | [Chemical Properties]
Light Yellow to Greenish Powder | [Uses]
Labelled Topotecan (T542500). A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. | [Uses]
Labelled Topotecan. A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic | [Description]
Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin . Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay. Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively). Formulations containing topotecan have been used in the treatment of small-cell lung cancer. | [storage]
Store at -20°C | [References]
[1] ROTHENBERG M L. Topoisomerase I inhibitors: Review and update[J]. Annals of Oncology, 1997, 8 9: Pages 837-855. DOI: 10.1023/a:1008270717294
[2] J DANCEY EA E. Current perspectives on camptothecins in cancer treatment[J]. British Journal of Cancer, 1996, 74 3: 327-338. DOI: 10.1038/bjc.1996.362
[3] JHM SCHELLENS. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor[J]. British Journal of Cancer, 1996, 73 10: 1268-1271. DOI: 10.1038/bjc.1996.243
[4] GISELA CACERES. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.[J]. Anti-Cancer Drugs, 2003, 14 7: 569-574. DOI: 10.1097/00001813-200308000-00010 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|